Robert Haverly, MD
Ophthalmology · Erie, PANPI 1821080722
Payments from drug & device makers
Across 201 payments — averaging $421.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$81K
- Apellis Pharmaceuticals, Inc.$545
- Alcon$519
- Genentech USA, Inc.$420
- NEW World Medical,inc.$236
- Regeneron Healthcare Solutions, Inc.$218
- plus $1K from 21 others
Across 9 payments — averaging $1459.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$13K
What the payments were for
- Food & beverage$3,48032%
- Education$801%
- Other$7,47568%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 79 | $81,466 |
| Apellis Pharmaceuticals, Inc. | 16 | $545 |
| Alcon | 18 | $519 |
| Genentech USA, Inc. | 23 | $420 |
| NEW World Medical,inc. | 7 | $236 |
| Regeneron Healthcare Solutions, Inc. | 6 | $218 |
| AbbVie(2 entities) | 7 | $198 |
| Oyster Point Pharma, Inc. | 6 | $173 |
| Dompe US, Inc. | 1 | $125 |
| Astellas Pharma US Inc | 5 | $120 |
| Novartis | 3 | $58 |
| Carl Zeiss Meditec, Inc. | 1 | $58 |
| Eyevance Pharmaceuticals LLC | 4 | $54 |
| Biotissue Holdings Inc. | 4 | $52 |
| Shire North American Group Inc | 3 | $47 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $42 |
| Sun Pharmaceutical Industries Inc. | 2 | $41 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $38 |
| Kala Pharmaceuticals, Inc. | 2 | $36 |
| Sight Sciences, Inc. | 2 | $36 |
| Thea Pharma Inc. | 2 | $33 |
| Rxsight Inc | 1 | $27 |
| Bausch & Lomb Americas Inc. | 1 | $20 |
| Amgen | 1 | $18 |
| Aerie Pharmaceuticals, Inc. | 1 | $17 |
| Ziemer USA | 1 | $17 |
| Alcon Research LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$84,629 in reported general payments places this provider in the 90th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 49 | $20,635 |
| RocklatanNetarsudil Mesylat/Latanoprost | 24 | $13,178 |
| RhopressaNetarsudil Mesylate | 26 | $10,152 |
| Difluprednate | 75 | $8,105 |
| TyrvayaVarenicline Tartrate | 11 | $7,045 |
| Latanoprost | 524 | $6,852 |
| Travoprost | 29 | $5,573 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 201 | $4,562 |
| MoxifloxacinMoxifloxacin Hcl | 207 | $3,816 |
| Timolol Maleate | 162 | $3,386 |
| Brinzolamide | 11 | $3,319 |
| Brimonidine Tartrate | 109 | $2,762 |
| Prednisolone Acetate | 90 | $2,369 |
| Diclofenac Sodium | 219 | $2,104 |
| Fluorometholone | 23 | $1,509 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $17 | $23,33150 claims |
| AbbVieLumigan | $198 | $20,63549 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $173 | $7,04511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Erie
- David AlmeidaErie$6.3M
- William ChristieCranberry Township$5.2M
- Carl RegilloPlymouth Meeting$3.2M
- Erik KrugerKingston$3M
- Sunir GargPlymouth Meeting$2M
- Allen ChiangPlymouth Meeting$1.6M
- Julia HallerPhiladelphia$1.5M
- Mitchell FinemanPlymouth Meeting$1.3M
- Allen HoPlymouth Meeting$1.3M
- Brandon AyresBala Cynwyd$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.